Table 1. Correlation of CD39 expression with clinicopathological parameters of 162 BC patients.
| Parameters | No. of Patients | CD39 | P Value | ||
|---|---|---|---|---|---|
| Negative | Low expression | High expression | |||
| Gender | |||||
| Male | 129 | 39 (30%) | 34 (26%) | 56 (44%) | 0.538 |
| Female | 33 | 07 (21%) | 11 (33%) | 15 (46%) | |
| Age | |||||
| ≤ 65 | 48 | 13 (27%) | 12 (25%) | 23 (48%) | 0.782 |
| > 65 | 114 | 33 (29%) | 33 (29%) | 48 (42%) | |
| Smoking | |||||
| No | 31 | 06 (19%) | 06 (19%) | 19 (61%) | 0.128 |
| Yes | 120 | 35 (29%) | 35 (29%) | 50 (42%) | |
| Unknown | 11 | 05 (46%) | 04 (36%) | 02 (18%) | |
| Grade | |||||
| Low | 42 | 8 (19%) | 16 (38%) | 18 (43%) | 0.140 |
| High | 120 | 38 (32%) | 29 (24%) | 53 (44%) | |
| Tumor stage | |||||
| NMI | 96 | 11 (11%) | 35 (36%) | 50 (52%) | <0.001 |
| MI | 66 | 35 (53%) | 10 (15%) | 21 (32%) | |
| Tumor stage | |||||
| pTa | 71 | 09 (13%) | 24 (34%) | 38 (54%) | <0.001 |
| pT1 | 25 | 02 (08%) | 11 (44%) | 12 (48%) | |
| pT2 | 21 | 14 (67%) | 02 (10%) | 05 (24%) | |
| pT3 | 26 | 11 (42%) | 05 (19%) | 10 (39%) | |
| pT4 | 19 | 10 (53%) | 03 (16%) | 06 (32%) | |
| Treatment | |||||
| TUR | 87 | 09 (10%) | 32 (37%) | 46 (53%) | <0.001 |
| Cystectomy | 75 | 37 (49%) | 13 (17%) | 25 (33%) | |
| Recurrence* | |||||
| No | 37 | 04 (11%) | 14 (38%) | 19 (51%) | 0.970 |
| Yes | 50 | 05 (10%) | 18 (36%) | 27 (54%) | |
| Progression* | |||||
| No | 73 | 09 (12%) | 28 (38%) | 36 (49%) | 0.210 |
| Yes | 14 | 02 (14%) | 02 (14%) | 10 (71%) | |
*Only patients who underwent transurethral resection (TUR).